[HTML][HTML] An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

…, G Huitt, MF Iademarco, M Iseman… - American journal of …, 2007 - atsjournals.org
… These criteria fit best with Mycobacterium avium complex (MAC), M. kansasii, and M.
abscessus. There is not enough known about most other NTM to be certain that these …

[HTML][HTML] Treatment of multidrug-resistant tuberculosis

MD Iseman - New England Journal of Medicine, 1993 - Mass Medical Soc
The era of modern, predictably effective tuberculosis chemotherapy began in 1952. Since
then, strains of Mycobacterium tuberculosis have acquired resistance to various drugs, thus …

The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis

S Gelperina, K Kisich, MD Iseman… - American journal of …, 2005 - atsjournals.org
Nanoparticle-based drug delivery systems have considerable potential for treatment of
tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers …

[HTML][HTML] Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

M Goble, MD Iseman, LA Madsen… - New England journal …, 1993 - Mass Medical Soc
Background and Methods The frequency of infection with multidrug-resistant Mycobacterium
tuberculosis is increasing. We reviewed the clinical courses of 171 patients with pulmonary …

[HTML][HTML] Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

…, MG Hollm-Delgado, TH Holtz, MD Iseman… - 2012 - journals.plos.org
Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…

Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis

…, MLN Huynh, M Goble, MD Iseman - American journal of …, 2004 - atsjournals.org
Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains
that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive and …

[PDF][PDF] Guidelines for the management of drug-resistant tuberculosis

…, D Maher, J Grosset, W Harris, N Horne, M Iseman… - 1997 - apps.who.int
… 1 About one third of the world’s population is infected by M. tuberculosis. Worldwide in 1995
there … M. tuberculosis kills more people than any other single infectious agent. Deaths from …

Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance

A Mahmoudi, MD Iseman - Jama, 1993 - jamanetwork.com
Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of …
Heifets LB, Iseman MD. Radiometric method for testing susceptibility of mycobacteria to …

Tuberculosis therapy: past, present and future

MD Iseman - European Respiratory Journal, 2002 - Eur Respiratory Soc
… The bacillus of Calmette and Guérin (BCG), a living vaccine derived from an attenuated
strain of M. bovis (a very close relative of M. tuberculosis), has been given to nearly 5 billion …

Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases

…, M Goble, GA Huitt, MD Iseman… - Clinical Infectious …, 2004 - academic.oup.com
Aminoglycoside use is limited by ototoxicity and nephrotoxicity. This study compared the
incidences of toxicities associated with 2 recommended dosing regimens. Eighty-seven patients …